Literature DB >> 10493852

Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain.

J Kallen1, K Welzenbach, P Ramage, D Geyl, R Kriwacki, G Legge, S Cottens, G Weitz-Schmidt, U Hommel.   

Abstract

The lymphocyte function-associated antigen (LFA-1) belongs to the family of beta2-integrins and plays an important role in T-cell activation and leukocyte migration to sites of inflammation. We report here that lovastatin, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1. Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 alpha-chain called the I-domain. The first three-dimensional structure of an integrin inhibitor bound to its receptor reveals atomic details for a hitherto unknown mode of LFA-1 inhibition. It also sheds light into possible mechanisms of LFA-1 mediated signalling and will support the design of novel anti-adhesive and immunosuppressive drugs. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493852     DOI: 10.1006/jmbi.1999.3047

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  65 in total

1.  Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds.

Authors:  Motomu Shimaoka; Chafen Lu; Azucena Salas; Tsan Xiao; Junichi Takagi; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-04       Impact factor: 11.205

2.  Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation.

Authors:  Motomu Shimaoka; Tsan Xiao; Jin-Huan Liu; Yuting Yang; Yicheng Dong; Chang-Duk Jun; Alison McCormack; Rongguang Zhang; Andrzej Joachimiak; Junichi Takagi; Jia-Huai Wang; Timothy A Springer
Journal:  Cell       Date:  2003-01-10       Impact factor: 41.582

3.  Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils.

Authors:  Shuren Li; Robert Dudczak; Elisabeth Koller; Mehrdad Baghestanian; Minoo Ghannadan; Erich Minar; Christian Pirich; Peter Angelberger; Irene Virgolini; Mei Li; Peter Valent
Journal:  Eur J Clin Pharmacol       Date:  2003-09-10       Impact factor: 2.953

Review 4.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

5.  Activation of integrin beta-subunit I-like domains by one-turn C-terminal alpha-helix deletions.

Authors:  Wei Yang; Motomu Shimaoka; JianFeng Chen; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

6.  Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring.

Authors:  Wei Yang; Motomu Shimaoka; Azucena Salas; Junichi Takagi; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

Review 7.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

Review 8.  Structural basis of integrin regulation and signaling.

Authors:  Bing-Hao Luo; Christopher V Carman; Timothy A Springer
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

9.  A small molecule agonist of an integrin, alphaLbeta2.

Authors:  Wei Yang; Christopher V Carman; Minsoo Kim; Azucena Salas; Motomu Shimaoka; Timothy A Springer
Journal:  J Biol Chem       Date:  2006-10-05       Impact factor: 5.157

10.  A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon.

Authors:  Min Xiu Wan; Rene Schramm; Daniel Klintman; Karl Welzenbach; Gabriele Weitz-Schmidt; Henrik Thorlacius
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.